The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Source Reference: Janik A, et al "Efficacy and safety of esketamine nasal spray as monotherapy in adults with ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.